AI Article Synopsis
- Chronic disease patients' quality of life is affected by the number of medications they take daily, leading to a push for fixed-dose combination (FDC) therapies by pharmaceutical companies.
- The latest ESC/ERS guidelines recommend initial dual therapy combining an endothelin receptor antagonist (ERA) and a phosphodiesterase 5 inhibitor (PDE5-i) for newly diagnosed pulmonary arterial hypertension (PAH) patients at lower risk.
- While polypills may improve tolerability and reduce healthcare costs, there is limited current evidence on their effectiveness in PAH, highlighting the need for future research on their safety and efficacy.
Article Abstract
Quality of life of patients suffering from chronic diseases is inevitably conditioned by the number of pills taken during the day. To improve patients' tolerability, compliance and quality of life and reduce healthcare costs, pharmaceutical companies are focusing on the commercialization of fixed-dose combination (FDC) therapies. The last ESC/ERS guidelines for the treatment of pulmonary arterial hypertension (PAH) recommend initial dual combination therapy for newly diagnosed patients at low or intermediate mortality risk. In this regard, polypills including an endothelin receptor antagonist (ERA) and a phosphodiesterase 5 inhibitor (PDE5-i) could represent an useful therapeutic strategy, although with some limitations. To date, evidence about the use of FDCs in PAH is limited but future studies evaluating their safety and efficacy are welcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2024.132003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!